VRNA vs. TEVA, SMMT, ITCI, GMAB, MRNA, VTRS, RDY, ASND, SRPT, and PCVX
Should you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.
Verona Pharma vs.
Verona Pharma (NASDAQ:VRNA) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking.
In the previous week, Teva Pharmaceutical Industries had 21 more articles in the media than Verona Pharma. MarketBeat recorded 24 mentions for Teva Pharmaceutical Industries and 3 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 1.11 beat Teva Pharmaceutical Industries' score of 0.73 indicating that Verona Pharma is being referred to more favorably in the media.
Verona Pharma has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Verona Pharma's return on equity.
Verona Pharma has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Verona Pharma is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
85.9% of Verona Pharma shares are owned by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 4.8% of Verona Pharma shares are owned by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Teva Pharmaceutical Industries received 1002 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 80.73% of users gave Verona Pharma an outperform vote while only 67.87% of users gave Teva Pharmaceutical Industries an outperform vote.
Verona Pharma currently has a consensus price target of $69.14, suggesting a potential upside of 4.48%. Teva Pharmaceutical Industries has a consensus price target of $23.43, suggesting a potential upside of 49.13%. Given Teva Pharmaceutical Industries' higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Verona Pharma.
Verona Pharma has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.
Summary
Verona Pharma and Teva Pharmaceutical Industries tied by winning 9 of the 18 factors compared between the two stocks.
Get Verona Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verona Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:VRNA) was last updated on 3/26/2025 by MarketBeat.com Staff
